Melody Cobleigh

21.4k total citations · 7 hit papers
131 papers, 14.7k citations indexed

About

Melody Cobleigh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Melody Cobleigh has authored 131 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in Melody Cobleigh's work include HER2/EGFR in Cancer Research (49 papers), Cancer Treatment and Pharmacology (39 papers) and Breast Cancer Treatment Studies (21 papers). Melody Cobleigh is often cited by papers focused on HER2/EGFR in Cancer Research (49 papers), Cancer Treatment and Pharmacology (39 papers) and Breast Cancer Treatment Studies (21 papers). Melody Cobleigh collaborates with scholars based in United States, Canada and South Korea. Melody Cobleigh's co-authors include Kathy D. Miller, Dennis J. Slamon, David Cella, Louis Fehrenbacher, Maura N. Dickler, Debu Tripathy, Charles L. Vogel, Steven Shak, Julie R. Gralow and Nancy E. Davidson and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Melody Cobleigh

128 papers receiving 14.2k citations

Hit Papers

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for... 1996 2026 2006 2016 2007 1999 2002 1997 2005 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
    2007 2.3k citations Kathy D. Miller, Julie R. Gralow et al. profile →
  2. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
    1999 2.2k citations Melody Cobleigh, Charles L. Vogel et al. Journal of Clinical Oncology profile →
  3. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 1.5k citations Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology profile →
  4. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
    1997 1.5k citations Melody Cobleigh et al. Journal of Clinical Oncology profile →
  5. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
    2005 1.0k citations Kathy D. Miller, Melody Cobleigh et al. Journal of Clinical Oncology profile →
  6. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
    1996 593 citations Melody Cobleigh et al. Journal of Clinical Oncology profile →
  7. BRCA1Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
    1997 506 citations Melody Cobleigh et al. profile →

Peers

Melody Cobleigh
Comparison fields: 5 of 146
  • Oncology 10.5k
  • Molecular Biology 4.3k
  • Cancer Research 3.8k
  • Radiology, Nuclear Medicine and Imaging 3.0k
  • Pulmonary and Respiratory Medicine 2.8k
Replace Sabino De Placido with:
Sabino De Placido Italy
Evandro de Azambuja Belgium
Aňa Lluch Spain
Maureen Trudeau Canada
Adam Brufsky United States
Jungsil Ro South Korea
Suzette Delaloge France
Lyndsay N. Harris United States
Aditya Bardia United States
Sandra M. Swain United States
Sabino De Placido Italy View profile →
Citations per field, relative to Melody Cobleigh
Melody Cobleigh · 1×
Citations per year, relative to Melody Cobleigh
Melody Cobleigh · 1×

Countries citing papers authored by Melody Cobleigh

Since Specialization
Citations

This map shows the geographic impact of Melody Cobleigh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melody Cobleigh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melody Cobleigh more than expected).

Fields of papers citing papers by Melody Cobleigh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melody Cobleigh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melody Cobleigh. The network helps show where Melody Cobleigh may publish in the future.

Co-authorship network of co-authors of Melody Cobleigh

This figure shows the co-authorship network connecting the top 25 collaborators of Melody Cobleigh. A scholar is included among the top collaborators of Melody Cobleigh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melody Cobleigh. Melody Cobleigh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
303MO Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial
2025 ·ESMO Open ·(unknown), (unknown), Elena Elimova, Sun Young Rha, Rachel Goodwin, (unknown), Kyung-Woo Lee, (unknown), (unknown), Peter Kabos, M. Beeram, (unknown), Melody Cobleigh, (unknown), (unknown), (unknown)
1
2
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study
2024 ·Cardio-Oncology ·Jian Chu, (unknown), (unknown), Changli Wei, Melody Cobleigh, Ruta Rao, Steven B. Feinstein, Lydia Usha, Kathrin Banach, Jochen Reiser, Tochukwu Okwuosa
2
3
Comparison of gut microbiome composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples
2023 ·Frontiers in Microbiology ·(unknown), (unknown), (unknown), (unknown), Thomas R. Witt, Thomas E. Lad, Melody Cobleigh, Ece Mutlu
16
4
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial
2021 ·Journal of Clinical Oncology ·Melody Cobleigh, Stewart Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Thomas B. Julian, David S. Parda, Samantha A. Seaward, Dennis L. Carter, Janice A. Lyons, Melissa S. Dillmon, Gustav Magrinat, Vivek S. Kavadi, (unknown), (unknown), (unknown), Marianne K. Melnik, Sushil Beriwal, Eleftherios P. Mamounas, Norman Wolmark
17
5
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
2019 ·Clinical Cancer Research ·Melody Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb
23
6
Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination
2019 ·International Journal of Radiation Oncology*Biology*Physics ·Mudit Chowdhary, Neilayan Sen, Akansha Chowdhary, Lydia Usha, Melody Cobleigh, (unknown), Kirtesh R. Patel, Parul Barry, Ruta Rao
2
7
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
2019 ·The Oncologist ·Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter A. Kaufman, Ginny Mason, Joyce O’Shaughnessy, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Laura Chu, Haocheng Li, Vincent Antao, Sara A. Hurvitz
45
8
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
2018 ·Clinical Cancer Research ·Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh
63
9
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
2018 ·PLoS ONE ·(unknown), Lela Buckingham, Melody Cobleigh, Jacob Rotmensch, (unknown), Lydia Usha
2
10
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
2013 ·Clinical Cancer Research ·Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen, Gail H. Vance, Lang Li, Guanglong Jiang, Kathy D. Miller, Julie R. Gralow, Maura N. Dickler, Melody Cobleigh, Edith A. Perez, (unknown), Kirsten Vang Nielsen, Sven Müller, Ann D. Thor, George W. Sledge, Joseph A. Sparano, Nancy E. Davidson, Sunil Badve
47
11
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
2013 ·Breast Cancer Research and Treatment ·Kalliopi P. Siziopikou, Stewart Anderson, Melody Cobleigh, Thomas B. Julian, Douglas W. Arthur, Ping Zheng, Eleftherios P. Mamounas, Eduardo R. Pajon, Robert J. Behrens, Janice F. Eakle, (unknown), James N. Atkins, Jonathan Polikoff, Thomas E. Seay, Worta J. McCaskill-Stevens, Rachel Rabinovitch, Joseph P. Costantino, Norman Wolmark
45
12
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
2011 ·Clinical Cancer Research ·Adrian M. Jubb, Kathy D. Miller, Hope S. Rugo, Adrian L. Harris, (unknown), James D. Reimann, Melody Cobleigh, Maike Schmidt, Virginia K. Langmuir, Kenneth J. Hillan, Daniel S. Chen, Hartmut Koeppen
79
13
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
2008 ·Journal of Clinical Oncology ·Bryan P. Schneider, Μolin Wang, Milan Radovich, George W. Sledge, Sunil Badve, Ann D. Thor, David A. Flockhart, Bradley A. Hancock, Nancy E. Davidson, Julie R. Gralow, Maura N. Dickler, Edith A. Perez, Melody Cobleigh, Tamara Shenkier, Susan M. Edgerton, Kathy D. Miller
487
14
Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer
2006 ·Journal of Clinical Oncology ·Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh, Kathy S. Albain, (unknown), Lea Fuchs, Dennis J. Slamon
342
15
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
2004 ·Journal of Clinical Oncology ·Debu Tripathy, Dennis J. Slamon, Melody Cobleigh, Andrew Arnold, Mansoor N. Saleh, Joanne Mortimer, Maureen Murphy, Stanford J. Stewart
221
16
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer breakdown →
2002 ·Journal of Clinical Oncology ·Charles L. Vogel, Melody Cobleigh, Debu Tripathy, John Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael F. Press
1508
17
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer
2002 ·Annals of Oncology ·Kathy D. Miller, William J. Gradishar, Lynn M. Schuchter, J. A. Sparano, Melody Cobleigh, Nicholas J. Robert, (unknown), George W. Sledge
44
18
Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit
2001 ·Breast Cancer Research and Treatment ·R. Mass, Melody Cobleigh, Charles L. Vogel, DJ Slamon
2
19
First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer
2001 ·Oncology ·Charles L. Vogel, Melody Cobleigh, Debu Tripathy, John Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, (unknown), William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart
145
20
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
1994 ·Journal of Clinical Oncology ·Richard Ghalie, Carol M. Richman, (unknown), Melody Cobleigh, (unknown), (unknown), Bruce C. McLeod, S G Taylor, Leonard A. Valentino, J Wolter
22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Evandro de Azambuja Breakdown of academic impact, for papers by Aňa Lluch Breakdown of academic impact, for papers by Maureen Trudeau Breakdown of academic impact, for papers by Adam Brufsky Breakdown of academic impact, for papers by Jungsil Ro Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Lyndsay N. Harris Breakdown of academic impact, for papers by Aditya Bardia Breakdown of academic impact, for papers by Sandra M. Swain
Rankless by CCL
2026